Otterbein University

Digital Commons @ Otterbein
Nursing Student Class Projects (Formerly MSN)

Student Research & Creative Work

Summer 2018

Bacterial Vaginosis
Shreya Patel
shrepate@gmail.com

Follow this and additional works at: https://digitalcommons.otterbein.edu/stu_msn
Part of the Nursing Commons

Recommended Citation
Patel, Shreya, "Bacterial Vaginosis" (2018). Nursing Student Class Projects (Formerly MSN). 274.
https://digitalcommons.otterbein.edu/stu_msn/274

This Project is brought to you for free and open access by the Student Research & Creative Work at Digital
Commons @ Otterbein. It has been accepted for inclusion in Nursing Student Class Projects (Formerly MSN) by an
authorized administrator of Digital Commons @ Otterbein. For more information, please contact
digitalcommons07@otterbein.edu.

Shreya Patel, BSN, RN
Otterbein University
Westerville, Ohio

Bacterial Vaginosis
Introduction

Importance of Topic

Underlying Pathophysiology

Bacterial vaginosis (BV) is
described as a dysbiosis, or a
microbial imbalance in the
normal vaginal flora. Anaerobic
pathogenic bacteria outgrow the
normal, protective lactobacilli
leading to symptoms of
abnormal vaginal discharge and
malodor (Muzny & Schwebke,
2016).

The advanced practice nurse
(APN) should have significant
understanding of this disorder
since it is so prevalent and
recurring among the female
population. It has been noted by
a public health nurse employed at
a sexual health clinic that many
female patients diagnosed with
BV, either for the first time or
recurrently, are unaware of the
risk factors and methods of
prevention. It is important for
future clinicians to be
knowledgeable on the risk
factors, diagnostic criteria and
most current treatment so that
patients with BV are
appropriately treated and
educated to prevent recurrences
or serious complications.

Normal vaginal flora is predominated by lactobacilli that produce hydrogen-peroxide and lactic acid,
creating an acidic environment that is inhospitable to invading bacteria (Machado & Cerca, 2015).

BV affects 21 million women in
the United States alone (Bagnall
& Rizzolo, 2017). It is the most
common vaginal disorder in
women ages 15 to 44 years
(Centers for Disease Control and
Prevention [CDC], 2017).

Serious complications from BV
include preterm labor, pelvic
inflammatory disease,
postoperative infections and
increased risk for acquiring
sexually transmitted infections
(STIs), including HIV (Bagnall &
Rizzolo, 2017; Machado & Cerca,
2015).

•
•

Lactobacilli also secrete antimicrobial substances that have bactericidal activity or prevent the
adhesion of other microbes to the vaginal epithelial surface (Parma, Stella Vanni, Bertini, & Candiani,
2014).

•
•

In BV, the normal flora is replaced by Gardnerella vaginalis which leads to an alkaline environment
(Bagnall & Rizzolo, 2017).

•
•

G. vaginalis possesses 3 virulence factors that contribute to its pathogenicity in BV: ability to adhere
to vaginal epithelial cells, biofilm production, and cytotoxicity (Machado & Cerca, 2015).

G. vaginalis produces a biofilm on the epithelial surface which serves as a platform for other
pathogenic bacteria to adhere to. This biofilm also protects the pathogens by hindering antibiotic
penetration (Bagnall & Rizzolo, 2017).
Diagnostic criteria for BV includes the presence of clue cells in vaginal secretions. Clue cells are
desquamated biofilm-coated epithelial cells (Machado & Cerca, 2015).

Significance of Pathophysiology
There are several hypotheses on the pathogenesis of bacterial
vaginosis, however, the exact cause or mechanism that leads to
the microbial shift characteristic of BV is unknown (Muzny &
Schwebke, 2016).
Continued research is imperative for the development of more
efficacious treatments and improved patient education and
prevention.

50% of women treated for BV
have recurring symptoms within
12 months (Bagnall & Rizzolo,
2017).
Risk factors for BV include:
- Black or Hispanic ethnicity
- Douching
- Use of vaginal deodorants
- Smoking
- New or multiple sex
partners (SPs)
- Lack of condom use
- Women who have sex with
women
(Bagnall & Rizzolo, 2017).

Signs & Symptoms

Knowledge of the pathogenicity of G. vaginalis can be used to
create new medications targeting this microbe which appears to
be the primary invader in BV.
Research suggests that BV is an STI (Bagnall & Rizzolo, 2017;
Muzney & Schwebke, 2016). However, the Centers for Disease
Control and Prevention (CDC) does not classify BV as an STI, nor
does it recommend treatment for male partners of BV-positive
females (CDC, 2017).
From Lupin Pharmaceuticals. (2018). Retrieved from
https://www.keepherawesome.com/bacterial-vaginosis

Conclusive evidence is needed to determine the role of sexual
activity in the pathogenesis of BV. Proper classification of BV is
necessary for better prevention and control of the disease.

Thin, white or gray vaginal
discharge
Fishy odor, especially after
sex
Vaginal burning or itching
Dyspareunia (pain during
sexual intercourse)
Dysuria (pain when urinating)
Many women are
asymptomatic
(American College of Nurse
Midwives [ACNM], 2015)

Diagnosis
Diagnosis of BV is based on Amsel
criteria. Three of the four criteria
must be met for a positive
diagnosis:
• pH > 4.5 (measured with pH
strips)
• Thin, white or gray discharge
• Fishy odor after addition of
10% potassium hydroxide to
vaginal smear (Whiff test)
• At least 20% clue cells on wet
mount microscopy
(Bagnall & Rizzolo, 2017)

Treatment
The following treatment options
are recommended by the CDC for
bacterial vaginosis:
• Metronidazole 500 mg, orally
twice a day for 7 days
• 0.75% metronidazole gel, one
applicator intravaginally
every night for 5 nights
• 2% clindamycin cream, one
applicator intravaginally
every night for 7 nights
(Bagnall & Rizzolo, 2017)

Implications for Nursing Care
Because BV increases risk for acquiring STIs, including HIV, the CDC
recommends concurrent testing for Chlamydia, Gonorrhea,
Trichomonas and HIV when screening patients for bacterial vaginosis
(Bagnall & Rizzolo, 2017). Women being treated for BV should also be
counseled on safe sex practices.
Further research must be done that leads to the development of more
effective therapies and proper treatment guidelines for recurrent BV.
The APN should keep abreast of emerging research and new therapies
in order to provide the most exceptional patient care.
Yeast infections are a common consequence of BV treatment, and can
be easily treated with 150 mg oral Fluconazole (Bagnall & Rizzolo,
2017).
The APN should be mindful of the psychological impact this disease can
have on patients. Women may feel shame due to the discharge and
malodor, and avoid sexual activity (Bagnall & Rizzolo, 2017).
Patient education is a very important component of treatment and
prevention in bacterial vaginosis.
Patients prescribed oral metronidazole must be informed to avoid
alcohol while taking the medication to prevent a disulfiram-like
reaction (Bagnall & Rizzolo, 2017).
Patients should be provided with information on risk factors for BV and
counseled on behavioral prevention interventions.

Patients should be advised to take probiotics or eat yogurt with
lactobacilli to recolonize normal flora (ACNM, 2015).

Conclusions
Bacterial vaginosis affects 29% of women (Bagnall & Rizzolo, 2017). It is
vital that clinicians are knowledgeable about this disorder as they are
highly likely to encounter it in practice due to its high prevalence.
Clinicians must also stay informed of the latest
research and new therapies to best help their
References
patients as current therapies do not eradicate
the disease for almost half of affected women.
Having BV increases the risk of acquiring and
transmitting HIV (Machado & Cerca, 2015).
Thus, treatment and prevention of bacterial
vaginosis can also help reduce the spread of
STIs, including HIV.

